title: Long-term hepatitis B virus surface antigen decay in HIV-1/hepatitis B virus-coinfected adults initiating a tenofovir-containing regimen.
abstract: Hepatitis B virus (HBV) surface antigen (HBsAg) decay was explored in HIV-1- and HBV-coinfected patients beginning antiretroviral (ARV) therapy containing tenofovir disoproxil fumarate (TDF). The mean HBsAg decay was 0.38 log(10) IU/ml/year (95% confidence interval [CI], 0.71 to 0.05) in 18 patients with sustained plasma HIV-1 RNA suppression and 0.15 log(10) IU/ml/year (0.21 to 0.09) in 12 patients experiencing HIV-1 virologic failure due to suboptimal adherence to ARV (P = 0.17). We estimated that six of these 18 patients will attain HBsAg values below 10 IU/ml after 10 years of treatment.
authors: Université de Montpellier 1, INSERM Unité 1058, Montpellier, France. e-tuaillon@chu-montpellier.fr
authors: E
authors: E
authors: Tuaillon
authors: C
authors: C
authors: Lozano
authors: N
authors: N
authors: Kuster
authors: A
authors: A
authors: Poinso
authors: D
authors: D
authors: Kania
authors: N
authors: N
authors: Nagot
authors: A M
authors: AM
authors: Mondain
authors: G P
authors: GP
authors: Pageaux
authors: J
authors: J
authors: Ducos
authors: P
authors: P
authors: Van de Perre
authors: J
authors: J
authors: Reynes
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D060085:Coinfection / Q000188:drug therapy* / Q000821:virology*; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000302:isolation & purification; D006514:Hepatitis B Surface Antigens / Q000097:blood*; D019694:Hepatitis B, Chronic / Q000821:virology*; D006801:Humans; D008875:Middle Aged; D063065:Organophosphonates / Q000008:administration & dosage*; D000068698:Tenofovir; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D006514:Hepatitis B Surface Antigens; D063065:Organophosphonates; D000068698:Tenofovir; D000225:Adenine